New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Syndax Pharmaceuticals, Inc.
SNDX
Shape
US Flag

NASDAQ

Unprofitable

Unprofitable

2B

Biotechnology

Next Earning date - 07 Nov 2024

2B

Biotechnology

Next Earning date - 07 Nov 2024

18.75USD
Shape-0.24 ( -1.26%)
favorite-chart

Relative Strenght

23
favorite-chart

Volume Buzz

-47%
favorite-chart

Earning Acce

Yes
favorite-chart

Dist 52w H.

26%

Quote Panel

Shape
Updated October 26, 2024
1W -3.99 % 1M -0.74 % 3M -14.73 % 1Y 52.56 %

Key Metrics

Shape
  • Market Cap

    1.60B


  • Shares Outstanding

    85.10M


  • Share in Float

    79.45M


  • Dividende

    0


  • Earning Date

    07 Nov 2024


  • Price Target

    18.75


  • Average Volume

    970857


  • Beta

    0.906


  • Range

    12.185-25.34


  • Industry

    Biotechnology


  • Website

    https://www.syndax.com


  • Sector

    Healthcare


Fundamentals

Shape

N/A

P/E Ratio

395.33x

P/S Ratio

3.68x

P/B Ratio

0.0

Debt/Equity

-6543.2%

Net Margin

$-3.4

EPS

How SNDX compares to sector?

P/E Ratio

Relative Strength

Shape

SNDX

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$113M

Shape3127%

2025-Revenue

$3.11

Shape-289%

2025-EPS

$4M

Shape106%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

UBS

initialise

Previous: Not converted

2024-10-24

Now: Buy

Jefferies

initialise

Previous: Not converted

2024-06-28

Now: Buy

Guggenheim

initialise

Previous: Not converted

2023-07-11

Now: Buy

Earnings GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

N/A

-0.58
vs -0.40

Q4.22

arrow
arrow

N/A

-0.62
vs 1.81

Q1.23

arrow
arrow

N/A

-0.59
vs -0.63

Q2.23

arrow
arrow

N/A

-0.64
vs -0.62

Q3.23

arrow
arrow

N/A

-0.73
vs -0.58

Q4.23

arrow
arrow

N/A

-1.00
vs -0.62

Q1.24

arrow
arrow

N/A

-0.85
vs -0.59

Q2.24

arrow
arrow

N/A

-0.80
vs -0.64

Q3.24

arrow
arrow

N/A

-1.07
vs -0.73

Q4.24

arrow
arrow

N/A

-0.92
vs -1.00

Sales GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

-100%

NA  vs 12.4M

Q4.22

arrow
arrow

-100%

NA  vs 126.6M

Q1.23

arrow
arrow

NA

NA  vs NA

Q2.23

arrow
arrow

NA

NA  vs NA

Q3.23

arrow
arrow

NA

NA  vs NA

Q4.23

arrow
arrow

NA

536K  vs NA

Q1.24

arrow
arrow

NA

NA  vs NA

Q2.24

arrow
arrow

NA

3.5M  vs NA

Q3.24

arrow
arrow

NA

9.2M  vs NA

Q4.24

arrow
arrow

+4943%

27M  vs 536K

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

-11%

-0.11
vs -0.10

Q4.22

arrow
arrow

-8%

-0.08
vs -0.11

Q1.23

arrow
arrow

-8%

-0.08
vs -0.08

Q2.23

arrow
arrow

-11%

-0.11
vs -0.08

Q3.23

arrow
arrow

-14%

-0.14
vs -0.11

Q4.23

arrow
arrow

-13%

-0.13
vs -0.14

Q1.24

arrow
arrow

-15%

-0.15
vs -0.13

Q2.24

arrow
arrow

-16%

-0.16
vs -0.15

Institutionnal OwnershipShape

status-upQoQ

Q3.22

arrow
arrow

139

139
vs 122

14%

Q4.22

arrow
arrow

161

161
vs 139

16%

Q1.23

arrow
arrow

165

165
vs 161

2%

Q2.23

arrow
arrow

171

171
vs 165

4%

Q3.23

arrow
arrow

198

198
vs 171

16%

Q4.23

arrow
arrow

187

187
vs 198

-6%

Q1.24

arrow
arrow

195

195
vs 187

4%

Q2.24

arrow
arrow

200

200
vs 195

3%

Earnings Growth

Latest News